DoorDash Prices IPO At $102/shr, Above Estimated Range – Quick Facts

On-demand prepared food delivery service DoorDash Inc. said that it has priced its initial public offering of 33 million shares of its Class A common stock at $102.00 per share, which is above its previously estimated $90.00 and $95.00 per share range.

The offering reportedly values the company at about $32 billion based on common stock outstanding.

The company’s shares will begin trading on the New York Stock Exchange on December 9, 2020 under the symbol “DASH”. The closing of the offering is expected to take place on December 11, 2020.

DoorDash’s revenue more than tripled in the first nine months with majority of people across the nation are confined to their homes due to travel restrictions.

Herald afternoon quiz: December 9

Test your brains with the Herald’s afternoon quiz. Be sure to check back on nzherald.co.nz for the morning quiz tomorrow.

Woman shot, killed at Safeway in Lakewood

Lakewood police are investigating a shooting at a Safeway that left one woman dead Tuesday.

At 1:28 p.m., officers responded to the grocery store in the 9100 block of West Colfax Avenue and found a woman suffering from an apparent gunshot wound, police said in a news release. The woman was transported to a hospital where she was pronounced dead.

No arrests have been made, but police said they believe there is no immediate danger to the public.

The woman’s identity will be released after notification to her next of kin, police said.

IPO Lockup Expiration Alert: Generation Bio (GBIO)

The lockup period of Generation Bio Co. (GBIO) ends on December 9, 2020.

Generation Bio is a pre-clinical stage genetic medicines company developing non-viral gene therapies for rare and prevalent diseases of the liver and retina.

The company is expected to select a development candidate for hemophilia A and phenylketonuria in 2021, with IND-enabling studies also expected to be initiated next year.

The company made its debut on The Nasdaq Global Select Market on June 12, 2020, offering its shares at a price of $19 each and the 180 day lockup period expires tomorrow.

GBIO opened the first day of trading (i.e. June 12, 2020) at $22.15 and closed at $24.69 that day. The stock has thus far hit a low of $17.00 and a high of $55.72.

GBIO closed Tuesday’s trading at $48.85, up 1.26. But, in the after hours trading, the stock dropped 5.83% to $46.00.

IPO Lockup Expiration Alert: Burning Rock Biotech (BNR)

The lockup period of Burning Rock Biotech Ltd. (BNR) ends on December 9, 2020.

China-based Burning Rock Biotech focuses on the application of next-generation sequencing (NGS) technology in the field of precision oncology.

Last month, the company in-licensed Myriad Genetics’ myChoice tumor testing for homologous recombination deficiency in China.

In the third quarter, i.e., the company’s second quarter as a public company, total revenues jumped to RMB123.9 million (US$18.2 million), representing a 19.4% increase from RMB103.7 million for the same period in 2019.

Looking ahead, the company continues to expect total revenue of about RMB420 million (US$61.9 million) for full year 2020. The annual total revenue in 2019 was RMB381.6 million.

Burning Rock Biotech made its debut on The Nasdaq Global Select Market on June 12, 2020, offering its ADSs at a price of $16.50 per ADS and the 180 day lockup period expires on December 9.

BNR opened the first day of trading on June 12 at $22.80 and closed at $24.63 that day. The stock has thus far hit a low of $18.64 and a high of $32.40.

BNR closed Tuesday’s trading at $25.80, up 1.10%.

IPO Lockup Expiration Alert: Vaxcyte (PCVX)

The lockup period of Vaxcyte Inc. (PCVX) expires tomorrow (December 9, 2020).

Foster City, California-based Vaxcyte is a next-generation vaccine company developing novel vaccines for infectious diseases.

The lead vaccine candidate is VAX-24, a preclinical, 24-valent pneumococcal conjugate vaccine or PCV for invasive pneumococcal disease or IPD. The submission of IND to initiate a phase I/II clinical proof-of-concept study for invasive pneumococcal disease is expected in the second half of 2021, with topline data expected in 2022.

Also in the pipeline are:

VAX-A1, a prophylactic vaccine designed to prevent Group A Strep infections – with the final vaccine candidate expected to be nominated in 2021.

VAX-PG, a therapeutic vaccine designed to treat periodontal disease – with the final vaccine candidate expected to be nominated next year.

Vaxcyte made its debut on The Nasdaq Global Select Market on June 12, 2020, offering its shares at a price of $16 per share and the 180 day lockup period is all set to expires on December 9, 2020.

PCVX opened the first day of trading on June 12 at $20.80 and closed at $26.15 that day. The stock has thus far hit a low of $17.80 and a high of $58.47.

PCVX closed Tuesday’s trading at $32.80, up 2.63%.

Two oil wells bombed in oilfield in northern Iraq's Kirkuk – security sources

KIRKUK (Reuters) – Two oil wells were bombed inside a small oilfield on Wednesday and firefighters are working to put out the flames, oil officials and security sources said.

It was not immediately clear who was responsible for the bombings at Khabbaz oilfield, 20 km (12 miles) southwest of Kirkuk, the sources said.

The field produces about 25,000 barrels per day, oil officials said.